Medtronic (NYSE:MDT) said today that it won expanded FDA approval for its Resolute drug-eluting stent platform, now cleared for treating patients with coronary artery disease and de novo chronic total occlusion.
The new clearance covers the Resolute Onyx and Resolute Integrity devices, the Fridley, Minn.-based company said.
Read the whole story on our sister site, Drug Delivery Business News
The post Medtronic wins expanded FDA indication for Resolute DES appeared first on MassDevice.
from MassDevice https://ift.tt/2VpdlTL
Cap comentari:
Publica un comentari a l'entrada